The value of serum osteoprotegerin levels in patients with angina like chest pain undergoing diagnostic coronary angiography.

BACKGROUND Osteoprotegerin (OPG) is a member of the tumor necrosis factor superfamily.Recent evidence supports a relationship between serum OPG level and atherosclerosis. The aim of this study was to evaluate the possible association of OPG with the presence of coronary artery disease (CAD), its severity and prognosis in patients with chest pain and suspected coronary stenosis. METHODS In this cross-sectional analytic study, 180 candidates of elective coronary artery angiography were recruited. Serum level of OPG was measured by ELISA method in all patients and its relation with presence and severity of CAD based on a coronary atherosclerosis score (CAS) was assessed. Patients were followed for a mean period of about 24 ± 3.2 months and the relationship between OPG levels and future cardiac events were evaluated. RESULTS The mean serum level of OPG was 1637 ± 226 pg/mL in those with CAD and 1295 ± 185 pg/mL (nonparametric p = 0.001) in those without it. There was a significant direct correlation between the level of serum OPG and CAS (rho = 0.225, p = 0.002). The optimalcut-off point for predicting a significant coronary artery obstruction was a serum level of≥ 1412 pg/mL with a sensitivity and specificity of 60% and 57.8%, respectively. Major adversecardiac events (MACE) including cardiovascular death, admission with acute coronary syndrome,or heart failure, was significantly higher in those with higher OPG levels (22 [34.3%]vs. 15 [16%], p = 0.012). CONCLUSIONS There was a direct and significant correlation between the serum level of OPG and CAS. MACE occurred more commonly in those with higher baseline OPG levels.

[1]  S. Pedersen,et al.  Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. , 2012, The American journal of cardiology.

[2]  H. Parving,et al.  Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria , 2011, Cardiovascular diabetology.

[3]  Yujie Zhou,et al.  Plasma Osteoprotegerin Levels and Long‐Term Prognosis in Patients With Intermediate Coronary Artery Lesions , 2011, Clinical cardiology.

[4]  J. Hansen,et al.  Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study , 2011, Journal of thrombosis and haemostasis : JTH.

[5]  C. Mélot,et al.  Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. , 2010, Transplantation proceedings.

[6]  J. Igland,et al.  Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris. , 2010, Atherosclerosis.

[7]  P. Grzelak,et al.  Serum Osteoprotegerin Is a Predictor of Progression of Atherosclerosis and Coronary Calcification in Hemodialysis Patients , 2010, Nephron Clinical Practice.

[8]  Avijit Lahiri,et al.  Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. , 2010, Journal of the American College of Cardiology.

[9]  Yun Zhang,et al.  Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome , 2008, Acta cardiologica.

[10]  J. Herlitz,et al.  Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. , 2008, Journal of the American College of Cardiology.

[11]  A. Lahiri,et al.  The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. , 2006, Journal of the American College of Cardiology.

[12]  G. Hansson,et al.  Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[13]  A. Avignon,et al.  Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. , 2005, Diabetes care.

[14]  K. Sung,et al.  Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. , 2005, Clinical science.

[15]  A. Ruello,et al.  Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. , 2005, Journal of nephrology.

[16]  L. Hofbauer,et al.  Increased osteoprotegerin serum levels in men with coronary artery disease. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  Y. Ikari,et al.  Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.

[18]  G. Gensini,et al.  A more meaningful scoring system for determining the severity of coronary heart disease. , 1983, The American journal of cardiology.

[19]  P. Nestel,et al.  Severity of coronary atherosclerosis related to lipoprotein concentration. , 1978, British medical journal.

[20]  A. Wykrętowicz,et al.  The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. , 2011, Kardiologia polska.